

Supplementary Table1. univariate analyses between patients' overall survival and the expression of SLC2 family genes

Gene	Cutoff	Statistical value	P value	OR	2.5%CI	97.5%CI	P value
<i>SLC2A1</i>	706.29	2.12	0.15	1.62	0.82	3.23	0.17
<i>SLC2A3</i>	2984.88	2.78	0.10	0.54	0.27	1.07	0.08
<i>SLC2A4</i>	6.65	5.77	0.02	0.47	0.23	0.95	0.04
<i>SLC2A5</i>	1104.45	9.33	0.00	3.43	1.63	7.69	0.00
<i>SLC2A6</i>	192.44	3.28	0.07	1.50	0.76	3.02	0.25
<i>SLC2A7</i>	6.98	2.13	0.14	2607311.48	0.00	NA	0.99
<i>SLC2A8</i>	36.56	5.75	0.02	1.80	0.91	3.60	0.09
<i>SLC2A9</i>	193.78	0.09	0.77	0.60	0.30	1.19	0.14
<i>SLC2A10</i>	12.64	4.87	0.03	2.59	1.30	5.33	0.01
<i>SLC2A11</i>	139.12	2.31	0.13	1.53	0.78	3.08	0.22
<i>SLC2A12</i>	79.63	4.75	0.03	0.53	0.24	1.15	0.10
<i>SLC2A13</i>	141.70	6.73	0.01	0.34	0.14	0.75	0.01
<i>SLC2A14</i>	38.36	0.68	0.41	0.49	0.20	1.08	0.09

Supplementary Table2. Association between the clinicopathologic characteristics and patients' mortality in AML patients

Variables	Group	Alive	Dead	P value	Statistical method
Age		49.18	61.82	0.00	Student t test
PBMBC		58.84	58.6	0.95	Student t test
Gender	Female	26	54	0.09	Fisher's exact test
	Male	77	94		
Cytogenetic risk	Favorable	69	40	0.00	Fisher's exact test
	Intermediate	48	94		
	Poor	42	103		
FLT3-IDT	Negative	130	176	0.09	Fisher's exact test
	Positive	29	61		
CEBPA mutation	Negative	61	82	0.83	Fisher's exact test
	Positive	12	14		
<i>IDH1</i> mutation	Negative	61	88	0.19	Fisher's exact test
	Positive	14	11		
<i>DNMT3A</i> mutation	Negative	35	53	0.61	Fisher's exact test
	Positive	25	31		
<i>NPM1</i> mutation	Negative	116	178	0.56	Fisher's exact test
	Positive	43	57		
Chemotherapy	Yes	157	211	0.01	Fisher's exact test
	No	1	14		
Bone marrow transplant	Yes	70	42	0.00	Fisher's exact test
	No	88	183		
Targeted therapy	Yes	15	55	0.00	Fisher's exact test
	No	143	170		

Supplementary Table3. Linear regression analysis between clinicopathologic characteristics and SLC2 family gene expression in AML patients

Gene	Age	Gender (male)	PBMBC	Cytogenetic risk	FLT3- IDT	<i>CEBPA</i> mutation	<i>IDH1</i> mutation	<i>DNMT3A</i> mutation	<i>NPM1</i> mutation	Chemot herapy	Bone marrow transplant	Targeted therapy
<i>SLC2A1</i>			---	-				-				
<i>SLC2A3</i>			---		---	--			-			
<i>SLC2A4</i>	-		---		--				---			+
<i>SLC2A5</i>			-	--						-		+
<i>SLC2A6</i>						-		+	-			
								+				
<i>SLC2A8</i>						---	+					
<i>SLC2A9</i>			+++	+++		--			+++			
<i>SLC2A10</i>									+++	-		
<i>SLC2A11</i>			+++		+++			-	+++			
<i>SLC2A12</i>			++		--			-	---			
								-				
<i>SLC2A13</i>		-	+	+++				+	+++			
								+				
<i>SLC2A14</i>		---	---		---							

+, ++, +++ denote positive correlation with P value < .05, P value < .01 and P value < .001 respectively.

-, --, --- stand for negative correlation with P value < .05; P value < .01 and P value < .001 respectively.

Supplementary Table4. multivariate analyses between patients' overall survival and the mortality-associated features, *SLC2A5*, *SLC2A10* and *SLC2A13* expression levels in the validation set

Clinical features	OR (95%CI)	P-value
Age	1.03(1.02-1.05)	0.00
Cytogenetic risk	2.04(1.49-2.81)	0.
Chemotherapy	0.32(0.02-1.81)	0.29
Bone marrow transplant	0.3(0.18-0.52)	0.00
Targeted therapy	2.5(1.28-5.13)	0.00
<i>SLC2A5</i>	1.61(0.95-2.77)	0.08
<i>SLC2A10</i>	1.97(1.07-3.73)	0.03
<i>SLC2A13</i>	0.7(0.42-1.15)	0.16